Neoadjuvant Chemo-immunotherapy Followed by Concurrent Chemoradiotherapy and Immunotherapy in LACC

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

April 5, 2025

Primary Completion Date

December 30, 2026

Study Completion Date

December 30, 2028

Conditions
Locally Advanced Cervical Cancer
Interventions
DRUG

Neoadjuvant Chemotherapy (NACT)

"Neoadjuvant chemotherapy:~The neoadjuvant regimen prior to radiotherapy consists of paclitaxel 135-175 mg/m², cisplatin 75 mg/m², and Sintilimab 200 mg, administered every 3 weeks for 2 cycles.~Concurrent chemoradiotherapy:~Radical dose to the pelvic concurrent with cisplatin.~Consolidative immunotherapy:~Following the completion of chemoradiotherapy, Sintilimab consolidation therapy will be administered based on treatment efficacy and the patient's physical condition, for a total of 6 cycles, starting 3-4 weeks after chemoradiotherapy."

Trial Locations (1)

200127

Renji Hospital, Shanghai

All Listed Sponsors
lead

RenJi Hospital

OTHER